navamedic.comCrawled Nov 17, 2026
The page lists publications on individualized, fractionated levodopa treatment for Parkinson’s disease and minitablet therapy.
Navamedic ASA, listed on Euronext Oslo under NAVA, maintains transparent communication with capital markets.
Oslo, 21 December 2018 – Navamedic ASA (OSE: NAVA) announces that the Board of Directors has entered into a process for a potential acquisition of Novicus Pharma AS.
Oslo, 21 December 2018 – Navamedic ASA (Navamedic, OSE: NAVA) today announces that the Board of Directors has appointed Kathrine Gamborg Andreassen as Chief Executive Officer. Ms. Gamborg Andreassen will assume her position effective January 1, 2019.
Access to this section is restricted for regulatory reasons and requires user confirmation.
Navamedic fosters a culture of collaboration, innovation, and employee growth across global teams.
Position: Chief Scientific Officer (since January 2019) Number of shares in Navamedic ASA: 627,000 Year of birth: 1963
Position: Chief Financial Officer (since January 2026) Number of shares in Navamedic ASA: 20,000 Current external directorships: Chairman of the Board of Atello AS Year of birth: 1984
Position: Commercial Director Nordics, Head of Rx (since January 2026) Number of shares in Navamedic ASA: 0 Year of birth: 1973
Position: Chief Business Development Officer (since January 2023) Number of shares in Navamedic ASA: 575,000 Current external directorships: Nomvec AS Year of birth: 1959
Navamedic provides prescription medicines, consumer health products, and hospital therapies to address public health challenges like addiction, obesity, and Parkinson’s disease.
Navamedic emphasizes good corporate governance and open communication to foster confidence in its activities.
Navamedic operates responsibly and sustainably to build trust with stakeholders and society.
Norway: +47 67 11 25 40 Sweden: +46 31 335 11 90
Navamedic is a nordic pharma company and a reliable supplier of high-quality products.
Navamedic collaborates with industry, patient organizations, and healthcare systems to advance research, regulatory decisions, and medicine optimization.
Document version: 3.0 Effective date: 19 May 2026 Last updated: 19 May 2026
Navamedic reports a **13.2% revenue decline to NOK 120.6 million** in Q3 2026 while improving gross margins to **39.5%** (up from 37.5% in Q3 2025) through product mix adjustments and cost discipline. Adjusted EBITDA margin also rises to **8.8%** (from 8.1% year-over-year). The company attributes profitability gains to strategic shifts in product offerings and operational efficiency.
Navamedic schedules a live investor presentation of its third-quarter 2026 financial results on **October 29, 2026, at 08:30 CEST**. The event will be accessible via streaming and on-demand through the company’s investor portal. The session covers performance metrics and operational updates for the quarter.
Navamedic extends its distribution agreement for **Mysimba**, an oral obesity treatment, covering Nordic markets for another five years. The deal maintains Navamedic’s exclusive rights to distribute the prescription tablet in the region. The company’s partnership ensures continued access to the drug for patients across Denmark, Sweden, Norway, Finland, and Iceland.
Navamedic introduces **Virono**, the first over-the-counter, single-dose oral tablet for treating recurrent cold sores in adults. The product, available in Swedish pharmacies starting May 2026, creates a new category in over-the-counter cold sore treatments. Expansion efforts are underway in Finland, with plans to launch in the Netherlands later in 2026.
Navamedic launches **Flexilev** in its **OraFID dispenser** to improve Parkinson’s treatment by addressing motor fluctuations. The system allows precise dosing adjustments to mitigate efficacy gaps between doses, supporting tailored therapy for patients. OraFID’s design helps optimize levodopa delivery as symptoms vary throughout the day.